Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to seven new non-officer employees totaling 77,750 share options with an exercise price of $39.20 per share, equal to the closing price on the grant date. Grants were approved by the Compensation Committee with an effective date of October 2, 2025 and are intended as inducements under Nasdaq Listing Rule 5635(c)(4). Options vest over four years (25% at one year, then monthly 1/36th) and have a 10-year term, subject to the company’s 2025 Inducement Equity Incentive Plan and standard option agreement terms.
Business context: Xenon is a neuroscience-focused biopharmaceutical company advancing azetukalner in Phase 3 for epilepsy, MDD, and BPD and early-stage Kv7 and Nav1.7 programs in Phase 1 for pain.
Xenon Pharmaceuticals (Nasdaq: XENE) ha annunciato grant di equity di inducement a sette nuovi dipendenti non dirigenti per un totale di 77.750 opzioni su azione con un prezzo di esercizio di $39.20 per azione, pari al prezzo di chiusura alla data di grant. I grant sono stati approvati dal Compensation Committee con una data effettiva di 2 ottobre 2025 e sono intesi come inducements ai sensi della Nasdaq Listing Rule 5635(c)(4). Le opzioni maturano in quattro anni (25% dopo un anno, poi mensilmente 1/36) e hanno una durata di 10 anni, soggette al piano Inducement Equity Incentive del 2025 e ai termini standard degli accordi sull'opzione.
Contesto aziendale: Xenon è una società biofarmaceutica focalizzata sulle neuroscienze che sta avanzando azetukalner in fase 3 per epilessia, disturbo depressivo maggiore (MDD) e disturbo bipolare (BPD) e programmi Kv7 e Nav1.7 in fase 1 per il dolore.
Xenon Pharmaceuticals (Nasdaq: XENE) anunció otorgamientos de acciones por inducement a siete nuevos empleados no directivos por un total de 77,750 opciones sobre acciones con un precio de ejercicio de $39.20 por acción, igual al precio de cierre en la fecha de la subvención. Las subvenciones fueron aprobadas por el Comité de Compensación con una fecha efectiva de 2 de octubre de 2025 y se destinan como inducements conforme a la Regla de Listado de Nasdaq 5635(c)(4). Las opciones vencen en cuatro años (25% al año, luego mensualmente 1/36) y tienen un plazo de 10 años, sujeto al plan 2025 Inducement Equity Incentive y a los términos estándar del acuerdo de opción.
Contexto de negocio: Xenon es una empresa biofarmacéutica centrada en las neurociencias que avanza azetukalner en Fase 3 para epilepsia, trastorno depressivo mayor (MDD) y trastorno bipolar (BPD), y programas tempranos Kv7 y Nav1.7 en Fase 1 para el dolor.
Xenon Pharmaceuticals (Nasdaq: XENE)는 비임원 신규 직원 7명에게 총 77,750주 옵션의 inducement 주식 부여를 발표했으며, 행사가는 주당 $39.20로 grant일의 종가와 동일합니다. 보상위원회가 승인을 했고 발효일은 2025년 10월 2일이며, 나스닥 상장 규정 5635(c)(4)항에 따른 inducement로 의도되었습니다. 옵션은 4년에 걸쳐 평가되며(1년 시점에 25%, 이후 매월 1/36), 10년 만료 기간을 가지며, 2025년 Inducement Equity Incentive Plan 및 표준 옵션 계약 조건에 따라 적용됩니다.
사업 맥락: Xenon은 신경과학에 초점을 맞춘 생물의약 회사로, 뇌전증, 주요 우울 장애(MDD) 및 양극성 장애(BPD)에서 azetukalner를 3상으로 진행 중이며, 통증을 위한 Kv7 및 Nav1.7 프로그램도 1상에서 진행 중입니다.
Xenon Pharmaceuticals (Nasdaq: XENE) a annoncé des attributions d’actions d’inducement à sept nouveaux employés non cadres pour un total de 77 750 options d’achat avec un prix d’exercice de $39,20 par action, égal au cours de clôture à la date de la subvention. Les subventions ont été approuvées par le Comité de rémunération avec une date effective du 2 octobre 2025 et sont destinées à des inducements en vertu de la Nasdaq Listing Rule 5635(c)(4). Les options vestent sur quatre ans (25% après un an, puis mensuellement 1/36) et ont une durée de 10 ans, sous réserve du Plan 2025 Inducement Equity Incentive et des termes standard des accords d’options.
Contexte commercial : Xenon est une société biopharmaceutique axée sur les neurosciences qui fait progresser azetukalner en phase 3 pour l’épilepsie, le trouble dépressif majeur (MDD) et le trouble bipolaire (BPD) et des programmes précoces Kv7 et Nav1.7 en phase 1 pour la douleur.
Xenon Pharmaceuticals (Nasdaq: XENE) hat Inducement-Eigenkapitalzuteilungen an sieben neue Nicht-Führungskräfte beschlossen, insgesamt 77.750 Aktienoptionsscheine mit einem Aus exercise-Preis von $39,20 pro Aktie, entsprechend dem Schlusskurs am Zuschussdatum. Die Zuteilungen wurden vom Vergütungsausschuss genehmigt und haben ein Wirksamkeitsdatum von 2. Oktober 2025 und dienen als Inducements gemäß der Nasdaq Listing Rule 5635(c)(4). Optionen vesten über vier Jahre (25% nach einem Jahr, dann monatlich 1/36) und haben eine Laufzeit von 10 Jahren, vorbehaltlich des 2025 Inducement Equity Incentive Plans und der Standardbedingungen des Optionsvertrags.
Geschäftskontext: Xenon ist ein auf Neurowissenschaften fokussiertes Biopharma-Unternehmen, das Azetukalner in Phase 3 für Epilepsie, MDD und BPD vorantreibt und frühzeitige Kv7- und Nav1.7-Programme in Phase 1 für Schmerz behandelt.
Xenon Pharmaceuticals (Nasdaq: XENE) أعلنت عن منح أسهم تحفيزية لسبعة موظفين جدد غير تنفيذيين بإجمالي 77,750 خيار أسهم مع سعر ممارسة قدره $39.20 للسهم، مماثل لسعر الإغلاق في تاريخ المنح. تمت الموافقات على المنح من قِبل لجنة التعويض بتاريخ فعال هو 2 أكتوبر 2025 وهي مخصصة كإغراءات بموجب قاعدة إدراج ناسداك 5635(c)(4). تتدحرج الخيارات خلال أربع سنوات (25% بعد سنة واحدة، ثم شهرياً 1/36) ولها فترة صلاحية مدتها 10 سنوات، وفقاً لخطة Inducement Equity Incentive لعام 2025 وبنود العقد القياسي للخيارات.
سياق العمل: Xenon هي شركة أدوية حيوية تركز على الأعصاب وتطور azetukalner في المرحلة 3 لعلاج الصرع، والاضطراب الاكتئابي الشديد (MDD)، والاضطراب ثنائي القطب (BPD)، إضافة إلى برامج Kv7 وNav1.7 في المرحلة 1 للألم.
Xenon Pharmaceuticals (Nasdaq: XENE) 宣布向七名新的非管理层员工授予诱导性股票，共计77,750份股票期权，行使价格为每股$39.20，等同于授予日的收盘价。该等授予经薪酬委员会批准，生效日期为2025年10月2日，并作为依据纳斯达克上市规则5635(c)(4)的诱导性授予。期权在四年内归属（一年时归属25%，其后每月1/36归属），有效期为10年，受2025年诱导性股票激励计划及期权协议标准条款的约束。
业务背景： Xenon是一家专注于神经科学的生物制药公司，正在推进azetukalner在III期用于癫痫、重性抑郁障碍（MDD）和双相情感障碍（BPD）的治疗，以及疼痛领域 Kv7 和 Nav1.7 的早期阶段计划在一阶段进行研究。
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 77,750 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 2, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com
FAQ
What did Xenon (XENE) grant on October 2, 2025?
What is the exercise price and term of the XENE inducement options?
How do the XENE inducement options vest?
Why did Xenon issue these option grants under Nasdaq Rule 5635(c)(4)?
Do the inducement grants signal any change to Xenon’s clinical programs?
Where can investors find more information about Xenon (XENE)?
